{"entity":{"id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","aka":[],"tldr":"A phase 1/2 trial of PM8002 in small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07325136 by Bristol-Myers Squibb, with 240 participants planned, started 2026-02-03 and due to reach its primary completion in 2029-04-23. Interventions recorded: BMS-986525, Pumitamig. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07325136","url":"https://clinicaltrials.gov/study/NCT07325136"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07325136","phase":"1/2","setting":"A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer","sponsor":"Bristol-Myers Squibb","enrolled":240,"outcomes":[]},"route":"/trials/nct07325136/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}